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1 Regular physical activity and individualised exercise programmes (including muscle strengthening, cardiovascular
activity and ﬂexibility exercises) can reduce your pain, prevent worsening of your osteoarthritis, and improve your
daily function
4.5 90
2 If you are overweight and have osteoarthritis, it will be beneﬁcial to lose weight and maintain a healthy weight
through an individualised plan involving dietary changes and increased physical activity
7 96
3 Your osteoarthritis symptoms can often be eased signiﬁcantly without requiring an operation 8 96
4 Living a sedentary life could worsen your osteoarthritis, and also increases your risk of other lifestyle-related
diseases such as diabetes and cardiovascular disease
8.5 86
5 Individualised exercise is an integral component of treatment for everyone with osteoarthritis 9 100
6 Maintaining sufﬁcient muscle strength around the joints is important in reducing pain and maintaining function,
and if you require an operation will beneﬁt both pre- and post-operative periods of your treatment
9 84
7 Non-drug treatments have similar beneﬁts for your osteoarthritis symptoms to pain relieving drugs, but with very
few adverse side effects
9 83
8 Linking your individualised exercises to your other daily activities is a useful way to become more active 9.5 90
9 Individualised exercises only work for your osteoarthritis if you do them regularly 9.5 79
10 Actively taking part in self-management programs could beneﬁt your osteoarthritis 10.5 80
11 Treatment interventions and lifestyle changes for your osteoarthritis should be individualised and include long-and
short- term goals. These should be reviewed regularly with your health professionals
11 92
12 Osteoarthritis is not just a disease of the cartilage but affects your whole joint including muscles and ligaments 12 89
13 If you cannot achieve pain relief from your osteoarthritis, have undertaken a sustained period of recommended
conservative management and it is very difﬁcult to perform activities of daily living, joint replacement surgery is an
option
12 88
14 Small amounts of individualised exercise undertaken frequently can be beneﬁcial for your osteoarthritis 12 79
15 Joint damage on an x-ray does not indicate how much your osteoarthritis will affect you 13 98
16 The symptoms of osteoarthritis can vary greatly from person to person 13 85
17 You should avoid the use of non-steroidal anti-inﬂammatory drugs (NSAIDs) for your osteoarthritis overt he long-
term
13 72
18 Methods for you to self-manage your osteoarthritis should be discussed and agreed on by you and your health
professionals
14 75
19 Keyhole surgery (arthroscopy) that involves washout of the joint and joint scraping should not be used to treat your
pain unless there is a mechanical blocking of your joint
15.5 73
20 Osteoarthritis is not an inevitable part of getting older 17.5 81
21 You may get some pain relief from your osteoarthritis by using acetaminophen (paracetamol) medications 18 75
*The ranking for each statement in 1000 minds is calculated using the results of each participant's series of pairwise rankings for all statements. The smaller the number, the
higher the ranking
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disciplinary panel of OA experts (n¼85) and consumers who had been
diagnosed with hip and/or knee osteoarthritis (n¼15) were invited to
take part in a Delphi panel, via email. A modiﬁed Delphi method was
used, with statements extracted from the CPGs being presented for
evaluation, and panel members able to suggest additional statements in
the initial round. The Delphi panel members rated the importance of
each statement to be presented to consumers on a 5 point Likert scale
(Essential; Moderately important; Somewhat important; Not impor-
tant; Undecided/Don’t know). Percentage agreement between Delphi
panel members for each statement was determined, and when agree-
ment of 70% or more was achieved a statement proceeded to the next
round. In each subsequent round the results of the previous round were
summarized and fed back to participants. After three rounds of Delphi
survey, statements rated as Essential by at least 70% of the panel
members in the last round were then presented to a consumer focus
group to review and ensure consumer understanding of each message.
Finally, to prioritise the ﬁnal list of messages, conjoint analysis meth-
odology was applied via an online decision survey (1000Minds) com-
pleted by all panel members.
Results: The Delphi panel consisted of 51 international osteoarthritis
experts from 12 countries, with considerable OA experience as clini-
cians and/or researchers (median experience 20 years), and 9 con-
sumers from Victoria, Australia. Eighty-three statements extracted from
the CPGs were presented for evaluation in Round 1. A further 31
statements were suggested by panel members in this ﬁrst round. After
two further rounds of the Delphi process, 21 statements were rated as
essential by more than 70% of the panel. Eight of the statements in the
ﬁnal list were those originally suggested by panel members. Table 1
summarises the ratings of the ﬁnal Delphi round, and the priority
ranking for each statement in 1000 Minds. The prioritised list was well
aligned with the proportion of agreement overall. Priority themes were
evident in the ﬁnal statements with 10 of 21 statements relating to non-pharmacological conservative management and 6 of 21 statements
covering OA disease knowledge.
Conclusions: Through a multi stage process of consensus, involving
both OA experts and consumers 21 key messages have been identiﬁed
and prioritised. These messages can now form the foundation to create
evidence-based consumer educational materials, speciﬁcally targeted
to people living with hip or knee osteoarthritis. Importantly, this will
help to facilitate the translation of evidence into patient knowledge and
decisions related to OA.
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THE TYROSINE SULFATE DOMAIN OF FIBROMODULIN REPRESENTS A
NEW BINDING SITE TO COLLAGEN ENHANCING THE INTERACTION
AND FIBRIL FORMATION
V. Tillgren y, P. Onnerfjord y, M. M€orgelin y, A. Aspberg y,z,
D. Heinegard y. yClinical Sci., Lund, Sweden; zDept. of Biology,
Copenhagen, Denmark
Purpose: Fibromodulin is a collagen modulating protein belonging
to the family of the small leucine rich repeat proteoglycans. The
collagen modulating effect is demonstrated by in vitro ﬁbrillo-
genesis assay, resulting in retardation of turbidity compared to
ﬁbrillogenesis by collagen alone. Fibromodulin binds collagen via
the LRR domain, but whether the binding via the LRR has any role
in the assembly of the collagen is not clear. Fibromodulin null mice
have larger population of thinner collagen ﬁbers in ligaments
compared to the wild type mice and develop osteoarthritis due to
joint instability, indicating a regulatory role by ﬁbromodulin in vivo
as well. The N-terminal domain of ﬁbromodulin has a highly
negative charge due to the presence of the posttranslational
Fig. 2. ZA treatment could rescue the cartilage from serum-damage. (A-B)
ZA treatment improved Young’s modulus and dynamic modulus after
long-term culture. (C) GAG content of cartilage allografts was higher in ZA
rescued group after 4 weeks culture. (p<0.05) (D) Responsive rate of
spontaneous calcium signaling in chondrocytes were signiﬁcantly higher
in ZA treated group on days 2, 8, and 15 (after 1-week serum exposure);
(E-F) Live/Dead staining images 23 days after serum damage showed
fewer dead cells in ZA treated group.
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binding proteins. The aim of this work is to investigate binding of
this domain to collagen and its role in the regulation of collagen
ﬁbril assembly.
Methods: Different variants of ﬁbromodulin (full length, the N-terminal
domain of ﬁbromodulin and N-terminal truncated ﬁbromodulin) were
used to study interaction to collagen type I in solid phase assay and
surface plasmon resonance assay. Fibrillogenesis assay was used to
monitor changes in turbidity over time in the presence of the different
variants of ﬁbromodulin. Samples were collected from the ﬁbril for-
mation and visualized by EM negative staining. Speciﬁc binding sites for
ﬁbromodulin on the collagen monomers by detection with a gold-
labeled ﬁbromodulin speciﬁc antibody was also identiﬁed by EM neg-
ative staining.
Results: In solid phase assay, all three variants of ﬁbromodulin bind to
coated collagen type I, showing a novel binding site located in the N-
terminal domain of ﬁbromodulin.
By surface plasmon resonance a distinct difference in the dis-
sociation phase is observed. The dissociation of full-length ﬁbro-
modulin is much slower compared to the N-terminal truncated
variant of ﬁbromodulin, indicating contribution of both the N-ter-
minal site and the LRR-domain sites in binding to the collagen
molecule.
In an in vitro ﬁbrillogenesis assay, full-length and N-terminal trun-
cated ﬁbromodulin delays the ﬁbril formation. Adding the N-termi-
nal tyrosin sulfate rich domain instead accelerates the ﬁbril
formation, indicating that this domain binds and facilitates collagen
monomer assembly.
Samples taken after 24 h of ﬁbril formation in the presence of the dif-
ferent ﬁbromodulin variants or PBS were analysed by electron micro-
scopy. Full-length ﬁbromodulin shows the thinnest ﬁbers, but with the
most mature cross-striation. Presence of the N-terminal also results in
thinner ﬁbers compared to the control and the N-terminal truncated
variant but showed less maturation.
Further, all three variants bind to three common sites on the
collagen type I molecule, visualized by electron microscopy. An
informative observation by the electron microscopy is the ﬁnding
of full-length ﬁbromodulin binding two collagen molecules at the
same time. This shows engagement of the N-terminal and one of
the binding sites in the LRR region, concomitantly binding dif-
ferent collagen molecules, which can be important for the
assembly.
Conclusion: This work shows that the tyrosine sulfate rich domain
of ﬁbromodulin contributes to the high afﬁnity binding of the
ﬁbromodulin molecule to collagen. It inﬂuences and contributes to
the arrangement of the collagen molecules, which results in well
deﬁned, highly organized collagen ﬁbers.
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BISPHOSPHONATE RESCUES CARTILAGE FROM TRAUMA DAMAGE BY
PROMOTING MECHANICAL SENSITIVITY AND CALCIUM SIGNALING
IN CHONDROCYTES
Y. Zhou, M. Park, L. Wang, X. Lu. Univ. of Delaware, Newark, DE, USA
Purpose: Our previous studies have shown that zoledronic acid (ZA), a
bisphosphonate approved by FDA for osteoporosis treatment, can
suppress the development of post-traumatic osteoarthritis (PTOA) in a
DMM (destabilization of medial meniscus) mouse model (Fig. 1).
However, little is known about the chondroprotective mechanisms of
ZA. Here we hypothesized that 1) ZA can directly rescue cartilage from
traumatic damage during in vitro culture without the presence of bone,
2) ZA can promote the beneﬁcial effects of mechanical loading during in
vitro culture of cartilage, and 3) the chondroprotective effects of ZA are
related to the spontaneous calcium signaling in chondrocytes.
Methods: Rescue from Serum Damage: Cartilage allografts from calf
knee joints were cultured in serum medium (10% FBS) for 1 week to
simulate damage in joint bleeding. Samples were then cultured in
serum-free medium with/without 1 mM ZA for 4 weeks. Longitudinal
mechanical modulus and GAG content were measured, and sponta-
neous calcium responses of in situ chondrocytes were checked on day 1,
8, 15, and 29 using a confocal microscope.Mechanical Stimulation: Cartilage allografts were cultured in serum-
free medium with/without 1 mM ZA for 4 weeks, while mechanically
stimulated for 30 min daily (103% dynamic loading). The outcome
results included cell viability, gene expression levels using qRT-PCR
(Aggrecan, Type I and II collagen), longitudinal mechanical properties,
GAG and collagen content.
Results: Young’s modulus of serum damaged cartilage increased 200%
after 4-week rescue in ZA supplemented medium, while the non-ZA
group increased only 56% (Fig. 2A). GAG content in ZA treated samples
was 60% higher than the non-ZA group (Fig. 2C). The spontaneous
calcium responsive rate of chondrocytes in ZA group was 100% higher
than that in the non-ZA group after a 2-week rescue (Fig. 2D), andmuch
fewer dead cells were found in the ZA group (Fig. 2E & 2F). Linear
regression showed that the calcium responsive rate of chondrocytes
was positively correlated with mechanical modulus of cartilage (data
not shown).
Exposure to ZA had no beneﬁcial effects on the stiffness of cartilage in
static long-term culture (Fig. 3). However, ZA signiﬁcantly improved
both equilibrium and dynamic moduli of samples under mechanical
stimulation. ZA also promoted the cell viability in cartilage after long-
term culture (Fig. 4B, 4D), as well as the collagen content (Fig. 5B).
Expression levels of type I, II collagen and aggrecan genes were sig-
niﬁcantly higher in the ZA group at 2 week (Fig. 5C, 5D, and 5E).
Conclusions: ZA treatment can rescue the mechanical integrity of
serum-damaged cartilage during in vitro culture, indicating the chon-
droprotective mechanism of ZA may be through the direct regulation of
chondrocyte mechanotransduction activities. This conclusion was fur-
ther supported by the fact that ZA can promote the beneﬁcial effects of
mechanical stimulation during the in vitro culture of cartilage allografts.
We also showed that the chondroprotective action of ZAwas correlated
with more robust spontaneous calcium signaling in chondrocytes.
Fig. 1. Continuous administration of zolendronic acid (ZA), an FDA
approved bisphosphonate to treat bone loss, suppressed the development
of post-traumatic OA in a DMM mouse model. A) Histological analysis
showed minor cartilage degeneration in ZA treated mouse. B) Cartilage
damage score of tibia and femur were much lower in drug treated group.
